SAM
KALV

Sectoral Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Sectoral Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,551
Closed -$389K – 76
2019
Q2 		$389K Hold
17,551
– – 0.05% 74
2019
Q1 		$502K Hold
17,551
– – 0.06% 77
2018
Q4 		$347K Hold
17,551
– – 0.05% 73
2018
Q3 		$388K Buy
+17,551
New +$237K 0.04% 94

Other funds holding KALV

SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sectoral Asset Management's KALV Position: Q3 2019 in Review

Sectoral Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q3 2019, closing a stake of 17,551 shares — an estimated $389K sold.

Sectoral Asset Management first reported a position in KALV in Q3 2018 and held it in 4 quarters. The position peaked at $502K in Q1 2019. 76 funds tracked by Wall St. Rank hold KALV as of Q3 2019.

  • Sectoral Asset Management reported no remaining KalVista Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Sectoral Asset Management sold 17,551 KalVista Pharmaceuticals shares in Q3 2019, an estimated $389K.
  • Sectoral Asset Management first reported a position in KalVista Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • Sectoral Asset Management's KalVista Pharmaceuticals position peaked at $502K in Q1 2019.
  • 76 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2019.

Based on Sectoral Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.